Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M35.9Revenue (TTM) $M0.1Net Margin (%)-39,128.0Altman Z-Score-37.2
Enterprise Value $M25.3EPS (TTM) $-0.8Operating Margin %-39,128.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-39,128.0Higher ROA y-yN
Price/Book4.210-y EBITDA Growth Rate %-16.3Quick Ratio4.6Cash flow > EarningsY
Price/Sales7055-y EBITDA Growth Rate %14.1Current Ratio4.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-111.5Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-129.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M25.4ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXCharles Brandes 2016-09-30 Buy $1.64 - $2.28
($1.98)
$ 1.41-29%New holding18,000
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 1.41-83%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 1.41-90%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-12-09Buy20,000$1.6-11.88view
Masterson Nola EDirector 2016-11-21Sell3,305$1.95-27.69view
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.9351.61view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.1819.49view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-85.02view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-85.03view
Masterson Nola EDirector 2014-09-15Buy200$14.34-90.17view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-89.86view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-89.82view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-90.58view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

More From Other Websites
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of... Dec 19 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 19 2016
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of... Dec 19 2016
Repros to Meet with the FDA for Phase III Proellex Program Dec 13 2016
How Bonanza Creek Energy Inc (BCEI) Stacks Up In Relation to Its Peers Dec 13 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 12 2016
Repros Requests Meeting With FDA to Discuss Phase 3 Requirements for Proellex® in the Treatment of... Dec 12 2016
7 Companies That Destroyed Shareholders Last Week Dec 10 2016
Repros Therapeutics Drops on FDA Vote Dec 07 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Dec 07 2016
FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism Dec 06 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
REPROS THERAPEUTICS INC. Financials Nov 17 2016
Repros Therapeutics upgraded by Ladenburg Thalmann Nov 16 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Nov 15 2016
Repros (RPRX) Reports Positive Top-Line Data on Proellex Nov 15 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Nov 14 2016
Repros Reports Topline Positive Clinical Data After Two 18 Week Courses of Proellex® Delivered... Nov 14 2016
Repros (RPRX) Loss Narrower Y/Y in Q3, Pipeline in Focus Nov 09 2016
REPROS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)